uniQure confirmed it will submit its BLA in Q3 2026, though there is still a required confirmatory study to conduct.

The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the questions I get more than any other is, “Jonathan, how do you ...

uniQure N.V. QURE on Friday reported initial six-month follow-up data from the first low-dose cohort in its ongoing Phase ...

The decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.

Learn more about whether uniQure N.V. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

A first-of-its-kind drug may slow the progression of Huntington's disease, a rare, fatal, neurodegenerative disorder.

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing ...

Shares of uniQure surged on Dec. 10 after the company gave investors great news regarding AMT-130, an experimental gene therapy it's developing to treat Huntington's disease. According to uniQure, the ...

Shares of uniQure N.V. (NASDAQ: QURE) are crashing today, down by 32.6% as of 11:19 a.m. ET. The steep decline came after the gene therapy specialist provided its second-quarter update Monday morning.

NAARDEN, The Netherlands--(BUSINESS WIRE)--Forbion Capital Partners, the leading Dutch VC firm investing in world-class healthcare technologies, is proud to announce that its portfolio company uniQure ...

Shares of uniQure NV (NASDAQ: QURE) are plummeting today, down by 40% as of 11:09 a.m. ET. The steep decline came after the company announced interim results from a phase 1/2 clinical study evaluating ...